Press release
Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1™ Watch for Consumers
On Its Anniversary, the Inventor of Measure-through Motion and Low Perfusion™ Pulse Oximetry Introduces the First Health Watch to Offer Accurate, Continuous
About this update from Masimo Corporation
[{"type":"text","content":"\nOn Its Anniversary, the Inventor of Measure-through Motion and Low Perfusion™ Pulse Oximetry Introduces the First Health Watch to Offer Accurate, Continuous Measurements\n\n IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (NASDAQ: MASI) marks its 33rd anniversary today by announcing the limited market release of the W1™ health watch for consumers. The first of its kind, the Masimo W1 offers accurate, continuous measurements and actionable health insights – from the leader in hospital pulse oximetry – in a personal, discreet, lifestyle-friendly wrist-worn wearable. Building on Masimo’s decades of leadership in creating revolutionary noninvasive blood parameter monitoring solutions, W1 provides accurate, continuous monitoring of multiple health parameters – including oxygen saturation (SpO2), pulse rate, perfusion index, PVi®, and respiration rate, alongside step count and fall detection.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005318/en/Masimo W1™ (Photo: Business Wire)\nIncorporated on May 2, 1989 as a garage startup dedicated to solving the “unsolvable” problem of inaccurate and unreliable conventional pulse oximetry under real-life conditions such as patient movement, Masimo and its breakthrough Measure-through Motion and Low Perfusion™ SET® pulse oximetry today touch hundreds of millions of lives around the world each year.1 SET® pulse oximetry has been shown in more than 100 independent studies to outperform other pulse oximetry technologies,2 and is the only pulse oximetry shown in numerous large studies – involving more than 300,000 infants – to improve critical congenital heart disease (CCHD) screening in newborns.3-13 SET® pulse oximetry has also been shown to improve outcomes for patients on opioids in post-surgical wards,14-17 reduce eye damage and blindness in the neonatal intensive care unit,18 and reduce mortality among Covid patients remotely monitored at home.19 Through Masimo’s continued focus on innovation and improvement, SET® has evolved to feature the industry’s highest accuracy specifications, on the new RD line of patient sensors; become tetherless, with the secure Bluetooth®-equipped continuous Radius PPG™; and now, as the foundational technology driving the W1, has become a truly lifestyle-friendly technology for consumers outside hos...